2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1178

Novel Quantification of MRI Provides a More Sensitive Outcome Measure Than Ramris
Abstract Number: 1664

Novel Risk Factors for Systemic Lupus Erythematosus (SLE) Flares in Patients with End-Stage Renal Disease: Is SLE in Patients with End-Stage Renal Disease a “sleeping beauty”?
Abstract Number: 1207

Novel Role of Liver X Receptor Alpha (LXRα) in the Attenuation of TLR Signalling: Implications in Congenital Heart Block
Abstract Number: 780

Novel Roles for Zyxin in the Pathogenesis of Giant Cell Arteritis
Abstract Number: 2979

Nucleic Acid Sensing Receptors TLR7, RIG-I and MDA5 Collaborate in Driving the Systemic IFN Signature and Amplify the Pathogenic Loop: Potential New Targets for Therapy in Primary Sjogrens Syndrome
Abstract Number: 756

Nucleosome, a Basic Repeating Unit of Chromatin, in Patients with Systemic Sclerosis: Possible Association with Immunological Abnormalities Via Abnormal Activation of T and B Cells
Abstract Number: 1464

Numbers of Circulating CD4 Positive CD28null T Cells Are Increased in Patients with Rheumatoid Arthritis and Are Associated with Rheumatoid Factor Positivity but Not Subclinical Cardiovascular Disease
Abstract Number: 1101

Numbness and Tingling: Neurological Symptoms in Fibromyalgia
Abstract Number: 263

Nutraceutical Products and Pain or Non-Pain Medications Use in Patients with Knee Osteoarthritis
Abstract Number: 2432

Nutritional Assessment in Patients with Systemic Lupus Erythematosus and Systemic Sclerosis
Abstract Number: 222

OA Phenotypes Rather Than Disease Stage Drive Structural Progression – Identification of Structural Progressors from 2 Phase III Randomized Clinical studies with Symptomatic Knee OA
Abstract Number: 1084

Obesity Is a Risk Factor for Depression in Systemic Lupus Erythematosus (SLE)
Abstract Number: 974

Obesity Paradox in Osteoarthritis Progression – What Effects Are We Measuring?
Abstract Number: 1874

Obesity Paradox in Recurrent Gout – a Metrological Clarification and Remedy
Abstract Number: 572

Objective Evaluation of Physical Functioning after TNFi Therapy in Ankylosing Spondylitis Patients; A Selection of Three Feasible Performance-Based Tests

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].